New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Slides:

Advertisements

Similar presentations

patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.

Advertisements

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with chronic systolic heart failure.

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)

Trial profile Fox K et al. Lancet 2008;372:

חזק בהגנה לבבית Valsartan in Heart Failure

The INTENSIFY study: practical daily effectiveness and tolerance of ivabradine in chronic systolic heart failure in Germany Zugck C, Martinka P, Stöckl.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

A step further in the management of stable coronary patients with ivabradine.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.

Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.

S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda and Karl Swedberg on behalf of the Investigators.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

ACCP Cardiology PRN Journal Club

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Extension studies show sustained benefits with ACEI TreatmentRamiprilEnalaprilEnalaprilRamipril Follow-up15 mos10 yrs12 yrs7.2 yrs Characteristic Clinical.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Increased mortality among patients taking digoxin—analysis from the AFFIRM study or Lack of evidence of increased mortality among patients with atrial.

Eric J Robinson, M.D. Cardiologist April 25, 2015

HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Revascularization in Patients With Left Ventricular Dysfunction:

Ivabradine – A new option for Heart Failure Patients

CLINICAL DILEMMAS IN HEART FAILURE:

EMPHASIS-HF Extended Follow-up

with type 2 diabetes without heart failure?

Heart Rate, HF Admissions, and Readmissions

Select Topics in Cardiovascular Medicine

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

Cost Effectiveness and Optimal Outcomes in HF

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Baseline characteristics of patients

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

G. Michael Felker et al. JCHF 2014;2:

Using Heart Rate as a Biomarker in Clinical Practice.

Case #1 Case #1 (cont) Case #1 (cont)

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

(p for noninferiority < 0.001)

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Baseline Characteristics of the Patients – Part I

Baseline Characteristics by hs-CRP

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

MOOD-HF Trial design: Patients with chronic systolic heart failure and comorbid depression were randomized to escitalopram (n = 185) vs. placebo (n = 187).

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Recurrence of HF hospitalization Total-time approach

Increase of physical activity over time associated with lower HF risk

International Journal of Cardiology

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a modest effect (ACEIs) or no impact (  -blockers) on QoL Some therapies that improve QoL (eg, inotropic agents) do not improve survival

 = 2.4, P<0.001 Baseline M12 Baseline M  6.7  4.3 KCCQ OSS Ekman I et al. Eur Heart J Online August 29. Ivabradine (n=842) Placebo (n=839) Ivabradine improves Health-related quality of life

Incidence of CV death or HF hospitalization (%) Time (months) Score ≥75* Score 50-<75* Score <50* Patients having a better quality of life have less risk of cardiovascular events P<0.001 Ekman I et al. Eur Heart J Online August 29. *KCCQ-OSS score in placebo group

P=<0.001 Higher HR reduction… greater quality of life with Ivabradine Ekman I et al. Eur Heart J Online August 29.

Conclusions Heart rate slowing with ivabradine in patients with chronic systolic HF in sinus rhythm with HR ≥70 bpm 1.Improves survival or heart failure hospitalizations 2.Improves HQoL